ConductScience.org, home

Paper36729264

Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.

Wang Y and 1 other. Cancer Metastasis Rev, 2023. Cited by 386 papers, by iCite.

Cite this record

ConductScience Library. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Papers, record 36729264. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36729264

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.
PubMed
Journal
Cancer Metastasis Rev
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
386
iCite
Relative citation ratio, by iCite
39.3
iCite
Revised in PubMed
2023-11-06
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang YYu
2Deng BBaochenghttps://orcid.org/0000-0003-4825-9794

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Humans
Oncogenes
Biomarkers
Signal Transduction
Molecular Targeted Therapy
Biomarkers, Tumor

Source PubMed

Download CSV of topics

References167

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
230970190Hepatocellular Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/30970190PubMed
325832714The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.Eur J Clin Invest2015https://conductscience.org/library/papers/25832714PubMed
426244070Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy.World J Hepatol2015https://conductscience.org/library/papers/26244070PubMed
521829020Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.Dig Dis2011https://conductscience.org/library/papers/21829020PubMed
69288757hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.Cell1997https://conductscience.org/library/papers/9288757PubMed
724400224From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence.Liver Cancer2013https://conductscience.org/library/papers/24400224PubMed
827602122Hepatitis B virus X protein mediates yes-associated protein 1 upregulation in hepatocellular carcinoma.Oncol Lett2016https://conductscience.org/library/papers/27602122PubMed
923504944Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells.Hepatology2013https://conductscience.org/library/papers/23504944PubMed
1032879846Novel molecular targets in hepatocellular carcinoma.World J Clin Oncol2020https://conductscience.org/library/papers/32879846PubMed
1131954490Epidemiology and surveillance for hepatocellular carcinoma: New trends.J Hepatol2020https://conductscience.org/library/papers/31954490PubMed
1232319693Epidemiology of Hepatocellular Carcinoma.Hepatology2021https://conductscience.org/library/papers/32319693PubMed
1316729298The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients.Hepatology2006https://conductscience.org/library/papers/16729298PubMed
1429388206Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide.Int J Cancer2018https://conductscience.org/library/papers/29388206PubMed
1532151618Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.J Hepatol2020https://conductscience.org/library/papers/32151618PubMed
1627746337Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.J Hepatol2017https://conductscience.org/library/papers/27746337PubMed
178707279Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma.Hepatology1996https://conductscience.org/library/papers/8707279PubMed
1828509392Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers.Int J Cancer2017https://conductscience.org/library/papers/28509392PubMed
1931119044Qidong: a crucible for studies on liver cancer etiology and prevention.Cancer Biol Med2019https://conductscience.org/library/papers/31119044PubMed
208580413Primary prevention of hepatocellular carcinoma.J Gastroenterol Hepatol1995https://conductscience.org/library/papers/8580413PubMed

See all 167 referencesDownload CSV of references

Cited by306

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 386 citations.

PMIDTitleJournalYearIn PapersSource
42964600An efficient hypochlorous acid fluorescence imaging strategy based on toehold-mediated strand displacement for distinguishing cancer cells from normal cells.RSC Adv2026https://conductscience.org/library/papers/42964600PubMed
42963792Critical roles of the long noncoding RNA SNHG4 in human cancers.Cell Div2026https://conductscience.org/library/papers/42963792PubMed
42952736
Survival benefits and prognostic models of surgical resection versus continued medical treatment in CNLC stage IIb/IIIa hepatocellular carcinoma after meeting resectability criteria following conversion therapy.
Front Oncol2026https://conductscience.org/library/papers/42952736PubMed
42878001ATF6-mediated GTPase RHOQ promotes liver cancer progression via enhancing aerobic glycolysis through PAK1 phosphorylation.Clin Transl Med2026https://conductscience.org/library/papers/42878001PubMed
42847779Deconformer: efficient cell-type composition profiling of cfRNA across diverse cell types.Brief Bioinform2026https://conductscience.org/library/papers/42847779PubMed
42801010miR-139-5p Targets CENPM to Suppress EMT and Malignant Progression of Hepatocellular Carcinoma via Regulating the Akt/mTOR Pathway and β-Catenin Nuclear Translocation.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42801010PubMed
42794416ADCK1 Regulates Mitochondrial Bioenergetics in Hepatocellular Carcinoma In Vitro.Int J Mol Sci2026https://conductscience.org/library/papers/42794416PubMed
42792641Rewiring of Molecular Networks Induced by the Combination of Loratadine, Raloxifene, and Sorafenib Leads to the Identification of Clinically Relevant Therapeutic Targets in Hepatocellular Carcinoma.Biomedicines2026https://conductscience.org/library/papers/42792641PubMed
42760533ZMIZ1 promotes aerobic glycolysis and development of hepatocellular carcinoma through inducing NOTCH1-mediated transcription of PYCR1.J Transl Med2026https://conductscience.org/library/papers/42760533PubMed
42747623Amino acid transporters in hepatocellular carcinoma: Gatekeepers of metabolic reprogramming.Mol Biol Rep2026https://conductscience.org/library/papers/42747623PubMed
42737438Integrated Transcriptomic Analyses Identify Four Prognosis-Associated Genes in Hepatocellular Carcinoma.Int J Mol Sci2026https://conductscience.org/library/papers/42737438PubMed
42729464Neutrophil Senescence Induced by Tumor-Derived HMGB1 Promotes Hepatocellular Carcinoma Progression through Neutrophil Extracellular Trap-Mediated Suppression of CD8+ T Cell Immunity.Cancer Commun (Lond)2026https://conductscience.org/library/papers/42729464PubMed
42724514Akkermansia muciniphila attenuates apatinib resistance in hepatocellular carcinoma through NF-κB-mediated reprogramming of tumor-associated macrophages.Transl Cancer Res2026https://conductscience.org/library/papers/42724514PubMed
42683851Synergistic effects of sorafenib and cilostazol in HepG2 cells.J Biosci2026https://conductscience.org/library/papers/42683851PubMed
42639779Effect of Jinlong capsule on the survival of patients with hepatocellular carcinoma: a propensity score matching study.J Tradit Chin Med2026https://conductscience.org/library/papers/42639779PubMed
42604028Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer.J Pharm Anal2026https://conductscience.org/library/papers/42604028PubMed
42593582DBF4B promotes hepatocellular carcinoma progression by regulating CCNA2 and PSMD11 expression.Mol Biol Rep2026https://conductscience.org/library/papers/42593582PubMed
42566146METTL3 promotes proliferation and invasion and inhibits ferroptosis in hepatocellular carcinoma by mediating m6A methylation modification of NUPR1.Mol Cell Biochem2026https://conductscience.org/library/papers/42566146PubMed
42506898ATP7A Orchestrates Tumor Progression and Cuproptosis in Hepatocellular Carcinoma via the LINC02038-miR-506-3p Regulatory Circuit.J Biochem Mol Toxicol2026https://conductscience.org/library/papers/42506898PubMed
42483739Targeting the 4EBP1/HSP90β/Nrf2 Axis Sensitizes β-catenin-mutant Hepatocellular Carcinoma to mTOR Inhibitors via Ferroptosis Induction.J Clin Transl Hepatol2026https://conductscience.org/library/papers/42483739PubMed

See all 306 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36729264

GET https://conductscience.org/api/papers/v1/36729264/references?page=2